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Abstract 
Purpose: To explore the outcomes and safety of atorvastatin/trimetazidine combination therapy in 
patients with chronic cardiac failure. 
Methods: A total of 144 patients with chronic cardiac failure were divided into test group (n = 72) and 
control group (n = 72). In addition to conventional anti-heart failure treatment, all patients in the two 
groups received atorvastatin, and those in the test group received, in addition, trimetazidine, for 28 
days. The clinical outcomes and safety profiles of the two groups were determined and compared. 
Results: Compared with pre-treatment stage, the left ventricular ejection fraction (LVEF), left ventricular 
fractional shortening (LVFS), left ventricular early diastolic peak velocity (E), as well as E to left 
ventricular end diastolic peak velocity (A) ratio (E/A ratio) for both groups improved significantly after 
treatment, while A and serum brain natriuretic peptide (BNP) level decreased significantly (all p < 0.05). 
Moreover, compared with control group, the increases in LVEF, LVFS, E, and E/A ratio of the test group 
were greater (42.81 ± 3.04 vs 47.97 ± 4.22 %; 31.01 ± 3.19 vs 36.02 ± 3.31 %; 57.44 ± 5.18 vs 61.93 ± 
5.42 cm/s; 1.02 ± 0.06 vs 1.19 ± 0.11, respectively), while the decreases in A and BNP level were 
greater (both p < 0.05) (57.34 ± 4.70 vs 52.37 ± 3.17 cm/s; 589.73 ± 41.19 vs 498.65 ± 30.89 pg/mL, 
respectively). Therapeutic outcomes were significantly better in the test group than in control group (p < 
0.05). Blood pressure, heart rate and serum levels of alanine transaminase (ALT) and creatinine did not 
differ significantly between the two groups (p > 0.05), but serum potassium and aspartate amino 
transferase levels were lower in the test group than in the control group (p < 0.05). 
Conclusion: Atorvastatin combined with trimetazidine effectively reduces BNP level and improves 
cardiac function in patients with cardiac failure. The safety profile of the combined therapy is good.  
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Chronic cardiac failure refers to cardiac systolic 
and/or diastolic functional insufficiency caused by 
various heart diseases; the cardiac output does 
not satisfy the metabolic demand. The condition 
manifests as blood stasis in the systemic and/or 
pulmonary circulation.  
 
Chronic cardiac failure develops during the 
terminal stage of heart disease and is associated 
with high-level morbidity and mortality [1,2]. The 
incidence of chronic cardiac failure has increased 
annually, and the fatality rate over the last five 
years has attained 50 % [3]. Such patients are 
unable to output all returning blood, reducing the 
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stroke volume, causing pulmonary venous stasis 
and even acute pulmonary oedema. The 
combination of oxygen uptake, bed rest, diuresis, 
and heart strengthening with prescription of β-
receptor inhibitors is the major therapeutic 
modality, but it is difficult to slow ventricular 
remodelling.  
 
Currently, many drugs are used to treat chronic 
cardiac failure, but their effects vary. Atorvastatin 
is an advanced statin that not only reduces the 
blood lipid level, protects the vessel endothelium, 
and delays atherosclerosis progression, but it 
also inhibits ventricular remodelling [4]. 
Trimetazidine, commonly used to treat angina, 
improves myocardial energy metabolism and 
protects both myocardial cells and blood vessel 
endothelia [5].  
 
The clinical effects of atorvastatin and 
trimetazidine and their safety profiles have been 
evaluated separately, but combined therapy has 
been rarely reported. We explored the outcomes 
of combined atorvastatin/trimetazidine therapy in 
patients who also received conventional anti-
heart failure treatment; we sought to provide a 





A total of 144 patients with chronic cardiac failure 
who underwent treatment in Taian City Central 
Hospital from February 2014 to June 2015 were 
selected. All met the chronic cardiac failure 
criteria of the New York Heart Association 
(NYHA). We excluded those who had undergone 
any other treatment during the prior 3 months 
and those diagnosed with acute myocardial 
infarction, a tumor, another organic lesion, 
hypotension, anaemia, or serum creatinine and 
potassium levels > 252.2 μmol·L-1 and > 5.5 
mmol·L-1, respectively. 
 
All patients were randomly allocated to a test or 
control group (72 patients/group). The study was 
approved by the Medical Ethics Committee of 
Taian City Central Hospital (approval no. 
TCCH20160301XH) and followed the relevant 
guidelines of the Declaration of Helsinki [6]. All 




All patients underwent conventional anti-heart 
failure treatment including oxygen 
supplementation, cardiac-strengthening 
exercises, diuresis, and prescription of 
angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers. All patients also 
took atorvastatin (Lipitor; Pfizer Inc., New York, 
USA; batch no.: J20120050) (10 mg daily for 28 
days), and patients in the test group took 
additional trimetazidine (Vasorel; Servier 
Pharmaceutical Co., Ltd., Tianjin, China; batch 





Cardiac function-associated indicators and brain 
natriuretic peptide (BNP) levels were compared 
before and after treatment. Cardiac functions 
including the left ventricular ejection fraction 
(LVEF), left ventricular fractional shortening 
(LVFS), left ventricular early diastolic peak 
velocity (E), left ventricular end diastolic peak 
velocity (A), and E/A ratio were examined via 
cardiac colour ultrasonography. Five millilitres of 
elbow venous blood were collected from each 
subject after fasting and 20 min of rest, both 
before treatment and 28 days after treatment 
commenced. The blood samples were 
centrifuged at 1,000 revolutions/min for 5 min to 
separate sera, which were stored at −20 oC. 
Serum BNP concentrations were determined 
using an enzyme-linked immunosorbent assay kit 
(Wuhan EIAab Science and Technology Co., 
Ltd., Wuhan, China), following the 
manufacturer’s instructions. The positive 
threshold of BNP concentration was set as 100 
ng/L.  
 
The clinical outcomes and safety profiles of the 
two groups were compared using the NYHA 
criteria. Treatment was considered significantly 
effective if cardiac function improved by two or 
more grades; palpitations, anhelation, or 
dyspnoea disappeared or were significantly 
relieved; lung rales or crepitations disappeared 
or were reduced; heart rate normalized; and/or 
the electrocardiogram findings improved. 
Treatment was considered effective if cardiac 
function improved by one or more grades and/or 
if palpitations, shortness of breath, or dyspnoea 
were relieved or lung rales reduced. Treatment 
was considered ineffective if cardiac function did 
not improve by one grade, disease became 
aggravated, or the patient died. Overall 
effectiveness was computed as in Eq 1. 
 
D (%) = {(a = b)/n}100 …………... (1) 
 
where D is the overall effectiveness, a the 
number of cases for whom treatment was 
significantly effective, b the number of cases for 
whom treatment was effective, and n the total 
number of patients. 
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To evaluate the safety of treatment, we 
monitored blood pressure, heart rate, and serum 
potassium, alanine transaminase (ALT), 





A database was established using SPSS ver. 
21.0 software; all data were expressed as mean 
± standard deviations (SD). The paired t-test was 
used to compare data obtained before and after 
treatment, and between-group comparisons were 
made using the two-sample t-test. Discrete and 
categorical data were expressed as percentages 
and compared using the chi-squared test. A p-







The demographic features of the two groups did 
not differ significantly (all p > 0.05, Table 1); 
therefore, the groups were comparable. 
 
Cardiac functions  
 
The cardiac function indicators prior to treatment 
did not differ significantly between the groups (all 
p > 0.05). Compared with before treatment, the 
LVEF, LVFS, E, and E/A ratio of both groups 
increased significantly, and A decreased 
significantly, after treatment (all p < 0.05). 
Compared with the control group, the 
improvements in the LVEF, LVFS, E, and E/A 
ratio of the test group were more obvious, as was 
the decrease in A (all p < 0.05, Table 2). 
 
BNP level  
 
Before treatment, the BNP levels of the test and 
control groups were 834.13 ± 22.46 and 832.87 ± 
23.37 pg/mL, respectively; the difference was not 
significant (t = 0.032, p = 0.973). The BNP levels 
of the test and control groups decreased 
significantly after treatment (test group: 834.13 ± 
22.46 vs 498.65 ± 30.89 pg/mL, t = 69.763, p = 
0.000; control group: 832.87 ± 23.37 vs 589.73 ± 
41.19 pg/mL), t = 38.875, p = 0.000, 
respectively). The decrease in the BNP level was 
greater in the test group (498.65 ± 30.89 pg/mL) 
than the control group (589.73 ± 41.19 pg/mL, t = 
13.793, p = 0.000). 
 
Effectiveness of the drug combination 
 
The overall effectiveness in the test group was 
87.5 % (63/72), thus greatly superior to that in 
the control group (65.3 %, 47/72; X2 = 14.941, p 
< 0.05, Figure 1). 
 
Table 1: Demographic data of the two groups (n = 72 in each group) 
 




Gender (male/female) 41/31 44/28 0.045 >0.05 
Average age (years) 60.8±8.7 61.2±8.6 0.286 >0.05 
Average disease course (years) 5.9±2.6 6.0±2.7 0.187 >0. 05 
Underlying 
disease (n) 
Hypertension 40 41 
0.108 >0.05 Coronary heart disease 15 14 
Rheumatic heart disease 11 9 




Grade II 43 42 
0.104 >0.05 Grade III 16 16 
Grade IV 13 14 
 
Table 2: Cardiac function indicators in both groups before and after treatment (n = 72 in each group) 
 
Indicator 
Test group Control group 
Before 





LVEF (%) 36.47±2.83 47. 97±4.22*# 36.50±2.82 42.81±3.04* 
LVFS (%) 22.44±2.12 36.02±3.31*# 22.40±2.09 31.01±3.19* 
E (cm/s) 50.78±4.57 61.93±5.42*# 50.81±4.60 57.44±5.18* 
A (cm/s) 63.39±4.17 52.37±3.17*# 63.42±4.14 57.34±4.70* 
E/A 0.81±0.09 1.19±0.11*# 0.79±0.07 1.02±0.06* 
Note: *P < 0.05 compared with before treatment; #p < 0.05 compared with control group 
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Figure 1: Cardiac function before and after treatment 
 
     Table 3: Medication safety in the two groups (n = 72 in each group) 
 
Parameter Test group Control group t P-value 
Blood pressure 
(mmHg) 
Systolic 115.5±15.2 121.5±13.6 1.921 0.059 
Diastolic 77.3±13.7 79.8±13.7 0.872 0.382 
Heart rate (beats/min) 76.4±7.1 76.2±6.7 0.142 0.894 
Serum potassium (mmol/L) 4.26±0.48 4.86±0.44 6.783 0.000 
AST(U/L) 22.92±7.05 26.46±8.24 2.219 0.034 
ALT(U/L) 24.98±7.51 28.23±8.66 1.907 0.064 
Creatinine (μmol/L) 82.23±24.51 93.05±28.75 1.954 0.054 
 
Medication safety  
 
The blood pressure, heart rate, and ALT and 
creatinine levels did not differ significantly 
between the two groups (all p > 0.05). The serum 
potassium and AST levels of the test group were 
significantly lower than those of the control group 
(both p < 0.05, Table 3). No adverse reaction 




Chronic cardiac failure, the terminal stage of 
many types of heart disease, is common and 
associated with complex clinical symptoms; the 
5-year survival rate of patients with chronic 
cardiac failure is close to that of patients with 
malignant tumours. The condition severely 
compromises physical and psychological health 
[7].  
 
Continual developments in cellular and molecular 
cardiology have allowed researchers to delve 
more deeply into the pathogenesis of chronic 
cardiac failure; many useful drugs have been 
developed [8,9]. The principal pathogenesis is 
activation of the renin-angiotensin and 
adrenergic system (RAAS). Such activation 
triggers a vicious cycle. Increased noradrenaline 
secretion caused by an increase in sympathetic 
excitability is also involved in the pathogenesis of 
chronic cardiac failure; the two factors interact 
such that continuous high-level sympathetic 
activation triggers excess renin secretion, 
exerting adverse effects on the heart [10-12]. In 
addition, RAAS activation enhances sympathetic 
excitability, aggravating the disease [13]. 
Therefore, the key goal of clinical treatment is to 
inhibit myocardial remodelling and excessive 
activation of the neuroendocrine system. 
 
The control group received conventional 
treatment in combination with atorvastatin, and 
the test group received additional trimetazidine. 
Atorvastatin, an inhibitor of HMG-CoA reductase, 
reduces cholesterol and low-density lipoprotein 
(LDL) levels by inhibiting cholesterol synthesis 
[14] and promoting LDL catabolism, thus 
reducing plasma lipid levels. Atorvastatin also 
effectively reduces the level of C-reactive protein, 
which promotes atherosclerosis development. 
The drug reduces the death rate and delays 
atherosclerosis progression [15]. Atorvastatin 
also regulates the immune system, reduces 
inflammatory reactions, and protects blood 
vessel endothelia, in turn protecting the 
myocardium and inhibiting myocardial 
remodelling [16]. Trimetazidine selectively 
inhibits the mitochondrial long-chain 3-keto-acyl-
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coenzyme athiolase but has no effect on 
haemodynamics in general or myocardial oxygen 
consumption in particular. Grube et al. [17] found 
that trimetazidine improved cardiac function and 
relieved myocardial ischaemia by partially 
blocking the β-oxidation of free fatty acids; the 
preferred myocardial energy substrate changed 
from fatty acids to glucose, which is associated 
with increased ATP production using less 
oxygen. Trimetazidine has shown great promise. 
Many clinical trials have found that the drug 
improves the LVEF, reduces the ventricular 
volume, and enhances quality of life [18,19]. 
Trimetazidine improved exercise tolerance, 
reduced the BNP level, and preserved cardiac 
function in patients with coronary heart disease 
[20]. 
 
This study found that cardiac function indicators 
and the BNP levels of the two groups improved 
significantly after treatment; this was especially 
true for the test group (p < 0.05). This indicated 
that combined atorvastatin and trimetazidine was 
useful for treating chronic cardiac failure 
associated with an elevated cardiac volume load, 
which in turn, increases ventricular pressure and 
ventricular wall tension and stimulates the 
synthesis of ventricular myocytes and BNP 
secretion. BNP triggers diuresis and natriuresis 
and inhibits the RAAS. Recent studies have 
suggested that monitoring the BNP level could 
aid in the early diagnosis of chronic cardiac 
failure and serve as an indicator of the curative 
effects of treatment and prognosis. Patients with 
more serious disease had higher BNP levels 
[21].  
 
In the present study, the decrease in the BNP 
level in the test group was more striking than that 
in the control group, indicating that the 
atorvastatin/trimetazidine combination was more 
effective than atorvastatin alone. The overall 
effectiveness rate in the test group was 87.5 %, 
much higher than that (65.3 %) in the control 
group (p < 0.05). Combination therapy was safe, 
as reflected by the absence of any effects on the 
serum potassium level, blood pressure, or renal 
or hepatic function. 
 
Limitations of the study 
 
The sample size was small; further studies 
involving much larger samples are required. The 
prognosis of patients treated with the 
atorvastatin/trimetazidine combination who were 
discharged after improved health status has not 
been adequately assessed in China. Had these 
cases been followed-up, more useful data would 




The findings indicate that atorvastatin/ 
trimetazidine combination improves the health 
conditions of patients, reducing BNP level of 
patients with chronic cardiac failure, and no 
medication-associated adverse reactions were 
reported. Thus, the combination therapy has 
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